These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 29084989)

  • 1. Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38
    Fumey W; Koenigsdorf J; Kunick V; Menzel S; Schütze K; Unger M; Schriewer L; Haag F; Adam G; Oberle A; Binder M; Fliegert R; Guse A; Zhao YJ; Cheung Lee H; Malavasi F; Goldbaum F; van Hegelsom R; Stortelers C; Bannas P; Koch-Nolte F
    Sci Rep; 2017 Oct; 7(1):14289. PubMed ID: 29084989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
    Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P
    Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826
    [No Abstract]   [Full Text] [Related]  

  • 3. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
    Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2553. PubMed ID: 30524421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD38-specific nanobodies allow
    Pape LJ; Hambach J; Gebhardt AJ; Rissiek B; Stähler T; Tode N; Khan C; Weisel K; Adam G; Koch-Nolte F; Bannas P
    Front Immunol; 2022; 13():1010270. PubMed ID: 36389758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immuno-targeting the multifunctional CD38 using nanobody.
    Li T; Qi S; Unger M; Hou YN; Deng QW; Liu J; Lam CMC; Wang XW; Xin D; Zhang P; Koch-Nolte F; Hao Q; Zhang H; Lee HC; Zhao YJ
    Sci Rep; 2016 Jun; 6():27055. PubMed ID: 27251573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells.
    Baum N; Eggers M; Koenigsdorf J; Menzel S; Hambach J; Staehler T; Fliegert R; Kulow F; Adam G; Haag F; Bannas P; Koch-Nolte F
    Front Immunol; 2021; 12():703574. PubMed ID: 34539634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
    de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
    J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma.
    Cho N; Ko S; Shokeen M
    Mol Imaging Biol; 2021 Apr; 23(2):186-195. PubMed ID: 32964391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs).
    Hambach J; Riecken K; Cichutek S; Schütze K; Albrecht B; Petry K; Röckendorf JL; Baum N; Kröger N; Hansen T; Schuch G; Haag F; Adam G; Fehse B; Bannas P; Koch-Nolte F
    Cells; 2020 Jan; 9(2):. PubMed ID: 32013131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma.
    Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2559. PubMed ID: 30459772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanobody-based dual epitopes protein identification (DepID) assay for measuring soluble CD38 in plasma of multiple myeloma patients.
    Li T; Li SL; Fang C; Hou YN; Zhang Q; Du X; Lee HC; Zhao YJ
    Anal Chim Acta; 2018 Oct; 1029():65-71. PubMed ID: 29907292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells.
    Hambach J; Fumey W; Stähler T; Gebhardt AJ; Adam G; Weisel K; Koch-Nolte F; Bannas P
    Front Immunol; 2022; 13():838406. PubMed ID: 35651607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells.
    An N; Hou YN; Zhang QX; Li T; Zhang QL; Fang C; Chen H; Lee HC; Zhao YJ; Du X
    Mol Pharm; 2018 Oct; 15(10):4577-4588. PubMed ID: 30185037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
    Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
    Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
    Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
    Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity.
    Yu T; Qiao C; Lv M; Tang L
    BMC Biotechnol; 2019 May; 19(1):28. PubMed ID: 31118070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
    Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
    Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
    [No Abstract]   [Full Text] [Related]  

  • 18. CD38 as a PET Imaging Target in Lung Cancer.
    Ehlerding EB; England CG; Jiang D; Graves SA; Kang L; Lacognata S; Barnhart TE; Cai W
    Mol Pharm; 2017 Jul; 14(7):2400-2406. PubMed ID: 28573863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ImmunoPET imaging of CD38 in murine lymphoma models using
    Kang L; Jiang D; England CG; Barnhart TE; Yu B; Rosenkrans ZT; Wang R; Engle JW; Xu X; Huang P; Cai W
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1372-1381. PubMed ID: 29450576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daratumumab in multiple myeloma.
    Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
    Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.